Company / R&D Expense
Design Therapeutics, Inc. R&D Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$44.4M
FY2025
5-year range
$6.1M / $57.1M
FY2021-FY2025
Trend
-22.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $6M to $44M over the past 4 years.
Based on SEC 10-K filings.
$44M in FY2025.
Improved from $6M to $44M over the past 4 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d expense decreased 22.3% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.59 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $44.4M | -22.3% |
| FY2024 | $57.1M | +841.6% |
| FY2021 | $6.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026